Ulipristal Acetate Tablets for Missed Abortion

Phase-Based Progress Estimates
Missed Abortion+4 More
Ulipristal Acetate Tablets - Drug
What conditions do you have?

Study Summary

This trial will study if using ulipristal acetate with misoprostol is an effective and safe way to treat early pregnancy loss.

Eligible Conditions
  • Missed Abortion
  • Anembryonic Pregnancy
  • Nonviable Pregnancy

Treatment Effectiveness

Study Objectives

3 Primary · 3 Secondary · Reporting Duration: From admission until day 30 follow up, +/- 7 days

Percentage of Participants Recruited to Study Protocol
Day 3
Number of Participants with Resolution of Early Pregnancy Loss following Study Intervention
Percentage of Participants Adherent to Study Protocol
Day 30
Median Acceptability of Study Intervention by Likert Scale
Number of Participants Needing Additional Medication for Resolution of Early Pregnancy Loss
Number of Participants Needing Surgical Management for Resolution of Early Pregnancy Loss
Number of Participants with Treatment-Related Side Effects and Adverse Events
Percentage of Participants Retained in Study Protocol

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

UPA 90mg
1 of 1

Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Ulipristal Acetate Tablets · No Placebo Group · Phase 2

UPA 90mgExperimental Group · 2 Interventions: Misoprostol Pill, Ulipristal Acetate Tablets · Intervention Types: Drug, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from admission until day 30 follow up, +/- 7 days

Who is running the clinical trial?

University of North Carolina, Chapel HillLead Sponsor
1,362 Previous Clinical Trials
3,927,634 Total Patients Enrolled
Jill M Hagey, MD, MPHPrincipal InvestigatorUniversity of North Carolina, Chapel Hill

Eligibility Criteria

Age 18+ · Female Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are female and you are at least 18 years old.
You are willing to comply with all study procedures and are available for the duration of the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 24th, 2021

Last Reviewed: November 28th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.